Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.63 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.51 |
| ▸ | PDE6D | O43924 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29493526 | 1.00 | CRBN (0.63) | CRBNDDB1GSPT1PDE6DSTAT3 | |
| Trifluoroacetic Acid SCHEMBL29493530 | 1.00 | CRBN (0.63) | CRBNDDB1GSPT1PDE6DSTAT3 | |
| Trifluoroacetic Acid SCHEMBL19747894 | 1.00 | CRBN (0.63) | CRBNDDB1GSPT1PDE6DSTAT3 | |
| Trifluoroacetic Acid SCHEMBL23705500 | 0.93 | CRBN (0.65) | CRBNDDB1GSPT1STAT3 | |
| SCHEMBL29400195 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL22636514 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL29098509 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL20919944 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL19747744 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL29403213 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-3474900-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223452-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BRD9, BRWD1, BRD1 | CRBN 186/4885DDB1 442/4885GSPT1 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.